Imipramine and Chlordiazepoxide in Depressive and Anxiety Disorders: I. Efficacy in Depressed Outpatients

Ronald S. Lipman, Lino Covi, Karl Rickels, Douglas M. McNair, Robert Downing, Richard J. Kahn, Virginia K. Lasseter, Vivian Faden

Research output: Contribution to journalArticlepeer-review

Abstract

We randomly assigned 425 outpatients, independently classified as primarily depressed by two trained psychiatrists, to double-blind treatment with imipramine hydrochloride, chlordiazepoxide hydrochloride, or placebo. Those patients who remained at least moderately depressed (following a twoweek placebo washout period) were treated for an additional eight weeks. An endpoint analysis of 387 patients who completed two or more weeks of medication disclosed early therapeutic advantages of chlordiazepoxide. By week 4 of treatment, however, imipramine produced more improvement than did placebo and chlordiazepoxide. By six and eight weeks a general, marked therapeutic advantage was found for imipramine relative to placebo and to chlordiazepoxide on measures of depression, anxiety, anger-hostility, interpersonal sensitivity, and global improvement. Chlordiazepoxide-treated patients generally did significantly better on sleep difficulty but significantly worse on anger-hostility and interpersonal sensitivity than did imipramine- or placebo-treated patients.

Original languageEnglish (US)
Pages (from-to)68-77
Number of pages10
JournalArchives of general psychiatry
Volume43
Issue number1
DOIs
StatePublished - Jan 1986

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Imipramine and Chlordiazepoxide in Depressive and Anxiety Disorders: I. Efficacy in Depressed Outpatients'. Together they form a unique fingerprint.

Cite this